Loading market dashboard
Purple Biotech Ltd.
PPBTHealthcareNASDAQIL
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Minimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the "Listing Qualifications Department") that the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market ("Nasdaq"), and is now compliant with applicable listing standards for continued Nasdaq listing.
Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development
